Pabrinex Treatment Aftercare Instructions

Key Takeaways

Pabrinex is a high-potency intravenous or intramuscular injection containing thiamine (B1), riboflavin (B2), pyridoxine (B6), nicotinamide (B3), and ascorbic acid (C) – used for Wernicke’s encephalopathy, acute alcohol withdrawal prophylaxis, and severe nutritional deficiency.

Wernicke’s encephalopathy dosing: 2 pairs (ampoule pairs) three times daily for a minimum of 2 days intravenously; alcohol withdrawal prophylaxis: 1 pair once daily for 3-5 days – always verify against the current BNF and trust formulary before prescribing.

IV Pabrinex must be diluted in 100ml NaCl 0.9% or dextrose 5%, infused over 30 minutes with resuscitation equipment immediately available due to anaphylaxis risk – a black-box safety concern that demands careful monitoring.

Pabau’s clinical record system and digital forms enable structured documentation of Pabrinex administration, dosing, and patient monitoring – critical for compliance, audit trail, and safe prescribing workflows.

Download Your Free Pabrinex Clinical Reference Guide

Pabrinex is one of the most critical injectable vitamin preparations in UK secondary and tertiary care, yet prescribing errors, dosing confusion, and administration mistakes remain common among junior doctors and nursing staff. This clinical reference guide provides everything clinicians need to prescribe, administer, and monitor Pabrinex safely and effectively – covering indications, dose regimens aligned with the BNF and NHS formulary, IV and IM administration protocols, and practical guidance on managing shortage-driven alternatives.

What is Pabrinex? Composition and Clinical Purpose

Pabrinex is a high-potency intravenous or intramuscular injection containing four B vitamins and vitamin C in a single preparation:

• Thiamine (vitamin B1): 250mg per ampoule pair – essential for carbohydrate metabolism and neurological function; deficiency precipitates Wernicke’s encephalopathy in at-risk populations.
• Riboflavin (vitamin B2): 4mg per ampoule pair – cofactor in oxidative metabolism.
• Pyridoxine (vitamin B6): 50mg per ampoule pair – involved in neurotransmitter synthesis and immune function.
• Nicotinamide (vitamin B3): 160mg per ampoule pair – component of NAD, critical for cellular energy production.
• Ascorbic acid (vitamin C): 500mg per ampoule pair – antioxidant and cofactor in collagen synthesis.

Each unit of Pabrinex is supplied as an “ampoule pair” – one water vial and one concentrate vial that are mixed immediately before administration. The preparation is licensed only for intravenous or intramuscular use; it is never given orally. All prescribing decisions must be verified against the current BNF entry for vitamin B substances with ascorbic acid and your trust’s local formulary.

Pabrinex Indications: When to Prescribe

Pabrinex is indicated for three broad clinical scenarios, each with distinct dosing and urgency:

Wernicke’s encephalopathy is the highest-acuity indication and demands immediate recognition. Symptoms include ophthalmoplegia (eye movement abnormality), ataxia (coordination loss), and acute confusion – a medical emergency. If Wernicke’s is suspected clinically, do NOT wait for confirmation imaging; start Pabrinex immediately to prevent irreversible neurological damage. Mental health and addiction services staff should have a low threshold for Pabrinex use in patients with alcohol dependence, even in the absence of classic Wernicke’s triad, because subclinical thiamine deficiency is common.

Alcohol withdrawal prophylaxis is the most frequent clinical use. During acute alcohol withdrawal, cellular deficiency of thiamine and other B vitamins emerges rapidly due to malnutrition and impaired absorption. Pabrinex is given alongside benzodiazepines and supportive care to prevent seizures and Wernicke’s development.

Pabrinex Administration: IV and IM Routes

Pabrinex can be given by intravenous or intramuscular injection. Route selection depends on clinical urgency, patient factors, and local protocol. IV is preferred for Wernicke’s encephalopathy due to faster onset and higher bioavailability.

Intravenous Administration

Reconstitution: Pabrinex comes as two ampoules per pair. Using an aseptic technique, draw the contents of the water ampoule into a syringe, then inject into the concentrate ampoule. Do NOT add to the water ampoule. The final solution is clear and colourless.

1. Dilute the reconstituted ampoule pair in 100ml of either NaCl 0.9% (preferred) or dextrose 5%.
2. Infuse over a minimum of 30 minutes via a peripheral or central line.
3. Do NOT infuse faster than 30 minutes due to anaphylaxis risk.
4. Flush the line with saline after infusion is complete.
5. Ensure resuscitation equipment (adrenaline, antihistamines, airway kit) is immediately available at the bedside.

For automated workflow documentation, capture the dilution volume, diluent type, infusion rate, time started, time completed, and any adverse reactions in the patient record.

Intramuscular Administration

IM Pabrinex is used when IV access is difficult or unavailable. Reconstitute as above; inject the full ampoule pair (up to 2ml) into a large muscle mass (gluteal, deltoid, or vastus lateralis). IM injection can be painful; consider local anaesthetic infiltration or splitting across two sites if giving more than 1 ampoule pair. IM onset is slower than IV – reserve for less urgent situations or when IV is contraindicated.

Cautions, Contraindications and Safety

Anaphylaxis risk: This is the most important safety concern. Pabrinex carries a documented risk of anaphylactic reactions, including severe bronchospasm, cardiovascular collapse, and angioedema. Although rare, anaphylaxis has been fatal. Compliance protocols should mandate that clinicians have resuscitation equipment at the bedside before every IV infusion and remain present during infusion.

Absolute contraindications: Known hypersensitivity to any component. Thiamine hypersensitivity is extremely rare but documented.

Cautions (relative): Wernicke-Korsakoff syndrome (established neurological injury may not fully reverse even with treatment); severe hepatic impairment (vitamin metabolism may be altered); renal impairment (dose adjustment typically not needed, but clinical judgment advised). Always review concurrent medications – no major drug interactions with Pabrinex are documented, but note that monoamine oxidase inhibitors (MAOIs) theoretically interact with B vitamins.

Pregnancy and breastfeeding: Pabrinex is not contraindicated and is often used in pregnant women with alcohol withdrawal or hyperemesis gravidarum. B vitamins are essential micronutrients; the risks of deficiency typically outweigh theoretical risks of the preparation.

Monitoring During and After Pabrinex

Monitoring requirements depend on indication and clinical context:

• During IV infusion: Continuous observation for anaphylaxis (wheezing, hypotension, urticaria, angioedema). Have adrenaline 0.3-0.5mg IM drawn up and ready. Stop the infusion immediately if any sign of anaphylaxis emerges.
• Neurological response: In Wernicke’s encephalopathy, observe for improvement in ophthalmoplegia (eye movements normalise within 24-48 hours if treatment is early) and mental status. Ataxia improves more slowly over days to weeks.
• Alcohol withdrawal monitoring: Assess seizure risk, consciousness level, autonomic stability (heart rate, blood pressure, temperature). Pabrinex is adjunctive to benzodiazepines – do NOT rely on Pabrinex alone to prevent seizures.
• Serial vitamin levels: Not routinely needed; Pabrinex is therapeutic, not investigational. Baseline and follow-up thiamine or B12 levels may be ordered in complex nutritional deficiency cases.

Documentation in digital clinical records must capture: indication for Pabrinex, dose given, route, dilution, time infused, any adverse reactions, and clinician assessment of response. This creates an audit trail critical for compliance and medicolegal protection.

Pabrinex Shortage and Alternatives

Since 2021, intermittent shortages of Pabrinex have prompted the British Society of Gastroenterology to publish shortage guidance recommending alternatives when Pabrinex is unavailable. However, these alternatives are NOT equivalent:

• Thiamine monohydrate injection (unlicensed for IV use): Can be given IV at 100-500mg doses for Wernicke’s encephalopathy, but is unlicensed for this route. Check with pharmacy before use; anaphylaxis risk is lower but documented. Always clearly document “unlicensed use” in the patient record.
• High-dose oral thiamine: 100-500mg three times daily can be used for alcohol withdrawal prophylaxis or mild deficiency when IV access is unavailable or shortage prevents IV Pabrinex. Onset is slower (days vs hours) and absorption unreliable in alcoholic patients with gastric disease; reserve for lower-acuity situations.
• Other oral B-complex supplements: Commercial multivitamins are inadequate for acute deficiency states and should not replace Pabrinex.

Check NHS England Supply Chain Bulletin and your trust’s pharmacy department for the latest shortage status before prescribing alternatives. Unlicensed use requires explicit consent and documentation.

Streamline Clinical Documentation with Pabau

Pabau’s clinical record system and digital forms enable structured, compliant documentation of Pabrinex prescribing, administration monitoring, and patient outcomes – ensuring safety and audit readiness.

Book a demo

Side Effects and Adverse Reactions

Most patients tolerate Pabrinex well. Common side effects are mild and transient:

• Local site reactions (pain, erythema, induration at injection site) – more common with IM.
• Flushing and warmth during IV infusion.
• Mild headache or dizziness.

Serious adverse reactions (rare): Anaphylaxis (bronchospasm, hypotension, angioedema, urticaria) – medical emergency requiring immediate adrenaline IM 0.3-0.5mg and IV access. Discontinue Pabrinex and treat as per anaphylaxis protocol.

Report all serious adverse reactions to the Yellow Card Scheme (MHRA Yellow Card) and notify your trust’s medicines governance team.

Quick Reference: Pabrinex Dosing at a Glance

Use this simplified table for rapid bedside reference. Always verify against the BNF and trust formulary before prescribing.

Governance and Documentation

Digital forms and structured templates within clinic software help standardise Pabrinex documentation. Ensure your practice captures: indication, dose (number of ampoule pairs), route (IV/IM), dilution volume and diluent type, infusion rate or injection site, time given, clinician signature, and any adverse reactions observed. This audit trail is essential for CQC inspections, medicolegal protection, and clinical governance reviews.

For IV therapy clinics, Pabrinex prescribing and administration should be integrated into a centralised clinical record system so all team members (prescribers, nurses, administrators) can view the complete treatment history and monitoring data.

Conclusion

Pabrinex remains an essential medicine in UK acute and community medicine, particularly in the management of alcohol withdrawal and Wernicke’s encephalopathy. Correct dosing, safe IV administration with anaphylaxis readiness, and thorough documentation are non-negotiable. Use the downloadable template above to standardise aftercare and monitoring communication with patients and staff. For complex prescribing queries or shortage situations, contact your pharmacy team or clinical governance lead to ensure compliant, evidence-based practice.

Continue your research

Need structured IV administration protocols? IV therapy EMR software with automated infusion documentation ensures every administration is logged with time, dilution, and adverse reaction monitoring.

Want a digital consent and monitoring form? IV therapy complications guide outlines screening and management steps for practitioners designing patient consent forms.

Looking to improve team competency? Team management software enables assignment of training modules and competency tracking for all staff involved in Pabrinex administration and monitoring.

Frequently Asked Questions